Cargando…

SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir

BACKGROUND: The tide of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) pandemic has scoured the global community with India, from 30 January 2020 to 30 September 2021, reporting 33,739,980 confirmed cases and over 448,090 deaths from coronavirus disease (COVID-19). Serologic testing for...

Descripción completa

Detalles Bibliográficos
Autores principales: Kousar, Rafiya, Sabah, Iram, Qazi, Tanzeela B., Haq, Inaamul, Qurieshi, Mariya A., Khan, Shahzada Muhammad Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480693/
https://www.ncbi.nlm.nih.gov/pubmed/36119315
http://dx.doi.org/10.4103/jfmpc.jfmpc_2012_21
_version_ 1784791095017734144
author Kousar, Rafiya
Sabah, Iram
Qazi, Tanzeela B.
Haq, Inaamul
Qurieshi, Mariya A.
Khan, Shahzada Muhammad Salim
author_facet Kousar, Rafiya
Sabah, Iram
Qazi, Tanzeela B.
Haq, Inaamul
Qurieshi, Mariya A.
Khan, Shahzada Muhammad Salim
author_sort Kousar, Rafiya
collection PubMed
description BACKGROUND: The tide of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) pandemic has scoured the global community with India, from 30 January 2020 to 30 September 2021, reporting 33,739,980 confirmed cases and over 448,090 deaths from coronavirus disease (COVID-19). Serologic testing for SARS-CoV-2 infection among the general public will provide essential information regarding the risk of infection. So, the present study was conducted to provide relevant information on the proportion of people who hadexperienced either a recent or past infection. METHODOLOGY: A cross-sectional study was conducted among adults >18 years in the Department of Community Medicine, Government medical college, Srinagar. Blood samples of the participants were tested for the presence of SARS-CoV-2-specific IgG antibodies using a chemiluminescent microparticle immunoassay-based serologic test. RESULTS: A total of 2,107 participants took part in the study. The overall unadjusted seroprevalence of IgG antibodies against SARS-CoV-2 in our study was 49%. The age-adjusted seroprevalence was 52%. CONCLUSION: The findings of the study suggested that not only a large proportion (49%) of the participants had been infected with COVID-19 infection but many were also susceptible to infection. Therefore, infection control measures still need to be followed properly.
format Online
Article
Text
id pubmed-9480693
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-94806932022-09-17 SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir Kousar, Rafiya Sabah, Iram Qazi, Tanzeela B. Haq, Inaamul Qurieshi, Mariya A. Khan, Shahzada Muhammad Salim J Family Med Prim Care Original Article BACKGROUND: The tide of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) pandemic has scoured the global community with India, from 30 January 2020 to 30 September 2021, reporting 33,739,980 confirmed cases and over 448,090 deaths from coronavirus disease (COVID-19). Serologic testing for SARS-CoV-2 infection among the general public will provide essential information regarding the risk of infection. So, the present study was conducted to provide relevant information on the proportion of people who hadexperienced either a recent or past infection. METHODOLOGY: A cross-sectional study was conducted among adults >18 years in the Department of Community Medicine, Government medical college, Srinagar. Blood samples of the participants were tested for the presence of SARS-CoV-2-specific IgG antibodies using a chemiluminescent microparticle immunoassay-based serologic test. RESULTS: A total of 2,107 participants took part in the study. The overall unadjusted seroprevalence of IgG antibodies against SARS-CoV-2 in our study was 49%. The age-adjusted seroprevalence was 52%. CONCLUSION: The findings of the study suggested that not only a large proportion (49%) of the participants had been infected with COVID-19 infection but many were also susceptible to infection. Therefore, infection control measures still need to be followed properly. Wolters Kluwer - Medknow 2022-06 2022-06-30 /pmc/articles/PMC9480693/ /pubmed/36119315 http://dx.doi.org/10.4103/jfmpc.jfmpc_2012_21 Text en Copyright: © 2022 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Kousar, Rafiya
Sabah, Iram
Qazi, Tanzeela B.
Haq, Inaamul
Qurieshi, Mariya A.
Khan, Shahzada Muhammad Salim
SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir
title SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir
title_full SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir
title_fullStr SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir
title_full_unstemmed SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir
title_short SARS-CoV-2 specific IgG antibodies among participants presenting to a voluntary testing facility in Srinagar, Kashmir
title_sort sars-cov-2 specific igg antibodies among participants presenting to a voluntary testing facility in srinagar, kashmir
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480693/
https://www.ncbi.nlm.nih.gov/pubmed/36119315
http://dx.doi.org/10.4103/jfmpc.jfmpc_2012_21
work_keys_str_mv AT kousarrafiya sarscov2specificiggantibodiesamongparticipantspresentingtoavoluntarytestingfacilityinsrinagarkashmir
AT sabahiram sarscov2specificiggantibodiesamongparticipantspresentingtoavoluntarytestingfacilityinsrinagarkashmir
AT qazitanzeelab sarscov2specificiggantibodiesamongparticipantspresentingtoavoluntarytestingfacilityinsrinagarkashmir
AT haqinaamul sarscov2specificiggantibodiesamongparticipantspresentingtoavoluntarytestingfacilityinsrinagarkashmir
AT qurieshimariyaa sarscov2specificiggantibodiesamongparticipantspresentingtoavoluntarytestingfacilityinsrinagarkashmir
AT khanshahzadamuhammadsalim sarscov2specificiggantibodiesamongparticipantspresentingtoavoluntarytestingfacilityinsrinagarkashmir